Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Antibody drug conjugate

Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in...

Research Partnership

- PMLiVE

Clovis rockets on maintenance data in ovarian cancer

The US company plans to file ARIEL3 to the FDA within a few months

- PMLiVE

AbbVie appoints new GMs for France and the UK

Jérôme Bouyer and Pierre-Claude Fumoleau take up new roles at the pharma firm

- PMLiVE

AbbVie’s PARP inhibitor veliparib fails to deliver

Phase III trials show no increase in clinical benefit

- PMLiVE

AbbVie and J&J file first non-cancer use for Imbruvica with FDA

Seeks FDA approval to treat GVHD patients

Using service design to improve patients’ quality of life

Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.

Blue Latitude Health

- PMLiVE

Tesaro joins PARP parade with US approval of Zejula

Unlike its rivals Zejula doesn’t require a BRCA mutation in patients before use

- PMLiVE

Caring for prostate cancer patients

Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving. It’s important not to overlook the all too often ‘unsung heroes’...

Blue Latitude Health

- PMLiVE

Novartis’ Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 

- PMLiVE

Argos hit as kidney cancer immunotherapy fails phase III trial

Study discontinued as data shows renal cell carcinoma vaccine unlikely to meet targets

AstraZeneca AZ

AZ agrees to $320m deal for Zoladex

TerSera Therapeutics acquires rights to oncology drug in US and Canada

- PMLiVE

AZ moves closer to Lynparza filing in breast cancer

PARP inhibitor showed “statistically-significant and clinically-meaningful” improvement in phase III trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links